Aralez Pharmaceuticals Inc

Aralez Pharmaceuticals — Non-Deal Roadshow (April 2016)

18 slides from Aralez Pharmaceuticals's roadshow presentation, Apr 4, 2016

  1. Slide 1: Forward-looking statements

    This presentation includes certain statements that constitute “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements regarding our 2016 financial guidance, the anticipated April launch of Fibricor, includi

  2. Slide 2: Aralez: A Compelling Platform for Growth

    Aralez: A Compelling Platform for Growth Strong Management with History of Success Diversified, Growing Revenue Base with North American Focus Strong Balance Sheet & Financial Position Canadian Domicile & Irish Presence Offers Financial & Competitive Advantage $150M* ($75M equity/$75M convertible no

  3. Slide 3: The Aralez Investment Thesis

    The Aralez Investment Thesis Aralez is a new global specialty pharmaceutical company designed to: Maximize the value of expanded portfolio, growing revenue base and geographic footprint across North America and Europe Build on our anchor positions in cardiovascular disease and pain management and op

  4. Slide 4: Focus on Cardiovascular & Pain Therapies

    Focus on Cardiovascular & Pain Therapies YOSPRALA™: Combination of delayed-release aspirin and immediate-release omeprazole for the secondary prevention of heart attack and stroke in patients at risk for developing aspirin-associated gastric ulcers FDA PDUFA goal date of September 14, 2016; targeted

  5. Slide 5: Aralez: Regulatory Status

    Aralez: Regulatory Status U.S.: PA32540/PA8140 NDA filing (YOSPRALA) 505b(2) application Proposed label for secondary prevention of CVD per aspirin monograph (excluding acute MI) Resubmitted NDA March 14, 2016 using our new primary aspirin supplier and an alternative supplier FDA PDUFA goal date of

  6. Slide 6: Fibricor: Opportunity in Perspective

    Fibricor: Opportunity in Perspective Fibricor is a fenofibric acid formulation that is a lipid regulating agent indicated as adjunctive therapy to diet for treatment of severe hypertriglyceridemia (> 500 mg/dL), primary hypercholesterolemia or mixed dyslipidemia Fibricor and its Authorized Generic v

  7. Slide 7: YOSPRALA: Product Background

    YOSPRALA: Product Background YOSPRALA™: Combination of delayed-release enteric-coated (EC) aspirin (325mg or 81mg core) and immediate-release omeprazole (40mg) for the secondary prevention of heart attack and stroke for patients at risk for an aspirin-induced ulcer Fixed-dose aspirin/PPI tablet desi

  8. Slide 8: YOSPRALA: U.S. Market Opportunity

    YOSPRALA: U.S. Market Opportunity YOSPRALA has the ability to achieve mid single digit market share in the secondary prevention patient population Upon FDA approval, plan to launch YOSPRALA with ~110 sales professionals (including 25 previously hired for Fibricor), targeting top 29% of secondary pre

  9. Slide 9: YOSPRALA: Educational Initiatives

    YOSPRALA: Educational Initiatives Research CARDs* IMs PCPs (n=71) (n=69) (n=49) (n=50) (n=38) (n=37) According to our market research, physicians indicate intent to use YOSPRALA in ~14-18% of their aspirin + PPI / H2 antagonist patients without educational initiatives, increasing to ~17-26% with edu

  10. Slide 10: YOSPRALA: U.S. Market Share Opportunity

    YOSPRALA: U.S. Market Share Opportunity Q1. (n=268) Thinking of your secondary prevention patients, approximately what percent receive each of the following antiplatelet medications for secondary prevention of cardiovascular events? Q3. (n=268) First, based on the information you were provided, how,

  11. Slide 11: YOSPRALA: Preparations

    YOSPRALA: Preparations Confirmed launch pricing for YOSPRALA Received feedback from KOL, Professional, and Advocacy groups Developed comprehensive and logical commercial messaging platform Developed and tested compelling branded and unbranded platforms Received positive feedback regarding optimal pr

  12. Slide 12: Tribute History: A Canadian Growth Story

    Tribute History: A Canadian Growth Story Tribute, a Canadian specialty pharmaceutical company, founded in January 2006 as a private company Strong history of driving growth through value-creating acquisitions and partnerships Collatamp® G in May 2012 Bilastine in May 2014 Fiorinal®, Fiorinal® C, Vis

  13. Slide 13: Aralez: Canadian Portfolio Growth Drivers

    Aralez: Canadian Portfolio Growth Drivers Cambia® Exclusive license in Canada from Depomed, Inc. Cambia (diclofenac) was approved by Health Canada in 2009 for the acute treatment of migraine attached with or without aura in adults 18 years of age or older Durela® Exclusive license in Canada from Cip

  14. Slide 14: 2016 Financial Guidance

    2016 Financial Guidance Measure 2016 Guidance Net Revenues* $48 million to $58 million Non-GAAP SG&A Expenses** $85 million to $100 million Non-GAAP R&D Expenses ** $8 million to $12 million * Guidance on net revenues includes revenues from Tribute from February 6, 2016 through December 31, 2016, as

  15. Slide 15: Business Development: Framework and Focus

    Business Development: Framework and Focus Near-term EBITDA accretive* and revenue generating products Approved products in Cardiovascular and Pain anchor areas Opportunistic approach to other specialty therapeutic areas meeting specified criteria US, Canada and ex-North American geographies Aligned,

  16. Slide 16: Our Near Term Priorities

    Our Near Term Priorities Complete Integration of Tribute Pharmaceuticals Canada Inc. Continued financially disciplined build up of organization Prepare for sales force deployment in April 2016 to promote Fibricor Prepare for anticipated YOSPRALA launch in 4Q 2016, pending FDA approval, and execute a

  17. Slide 17: Corporate Overview & Strategic Vision

    “Corporate Overview & Strategic Vision” Dundee Investor Meetings April 4-6, 2016

  18. Slide 18: Aralez Pharmaceuticals: Breathing New Life Into Pharmaceuticals

    /rale2 Pharmaceuticals Breathing New Life Into Pharmaceuticals™ Dundee Investor Meetings “Corporate Overview & Strategic Vision” April 4-6, 2016

Aralez Pharmaceuticals — Non-Deal Roadshow (April 2016) on 6ix